Dermatology最新文献

{"title":"Patient perspectives on treatment outcomes and priorities in autoimmune bullous diseases: an exploratory survey among Dutch patients.","authors":"Marjolein A J Hiel, Eva W H Korte, Maria C Bolling, Joost M Meijer, Barbara Horváth","doi":"10.1159/000552182","DOIUrl":"https://doi.org/10.1159/000552182","url":null,"abstract":"<p><p>Introduction Autoimmune bullous diseases (AIBDs), comprising pemphigoid and pemphigus diseases, have seen limited therapeutic advances beyond rituximab for pemphigus vulgaris. As novel therapies are evaluated in clinical trials, well-defined, uniform and relevant outcomes with patient involvement are essential. To date, however, patient-reported outcomes remain underrepresented, leaving uncertainty about whether trial results genuinely reflect patients' expectations. This study examines perspectives of patients with AIBD on treatment outcomes and priorities to ensure that future research focuses on what matters most to them. Methods A cross-sectional study was conducted among Dutch patients with AIBD between October 2023 and January 2024, using a self-developed questionnaire with both closed- and open-ended questions to assess patient perspectives on treatment outcomes and priorities, key factors in choosing a treatment, and indicators of treatment success. Results Regarding skin and/or mucous membrane complaints, 'the formation of new blisters and wounds' emerged as the most important complaint a treatment should address for both pemphigoid (43%) and pemphigus (86%) patients. In open-ended questions, patients with pemphigoid most frequently prioritized 'pruritus' (44%), while patients with pemphigus emphasized 'pain' (39%). Most important concerns regarding physical and daily functioning were 'vision problems' (20%), 'sleep disturbances' (20%), and 'self-care difficulties' (23%) for patients with pemphigoid, whereas patients with pemphigus most commonly cited 'eating and/or swallowing difficulties' (57%) and 'daily activity limitations' (41%). Regarding emotional/psychological functioning, both subgroups prioritized 'anxiety and/or worry' as most important concern (pemphigoid: 28%, pemphigus: 43%). Side effects were identified as the most important factor in choosing a treatment (pemphigoid: 41%, pemphigus: 39%). The absence of one or more symptoms and clinical signs (i.e., 'no blisters') was mentioned as the most important indicator of treatment success (pemphigoid: 88%, pemphigus: 91%), although minimal clinical signs (i.e., 'minimal blisters') were also considered acceptable (pemphigoid: 25%, pemphigus: 13%). Conclusion Patients with pemphigoid and pemphigus exhibit some distinct treatment priorities, reflecting their distinct pathomechanisms. Nonetheless, both subgroups consistently prioritize not only the resolution of disease-specific clinical signs but also preservation of physical and psychological well-being, underscoring the need for more holistic and patient-centred outcome measurement to ensure the establishment of meaningful, AIBD subgroup specific treatment outcomes.</p>","PeriodicalId":11185,"journal":{"name":"Dermatology","volume":" ","pages":"1-18"},"PeriodicalIF":2.7,"publicationDate":"2026-04-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147765542","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparative Clinical and Histological Analysis of Bullous Pemphigoid: Immunotherapy-Associated vs. Spontaneous Onset Cases.","authors":"Thilo Gwerder, Reinhard Dummer, Thomas Kuendig, Jivko Kamarachev, Lukas Kraehenbuehl","doi":"10.1159/000552077","DOIUrl":"https://doi.org/10.1159/000552077","url":null,"abstract":"<p><strong>Introduction: </strong>Immune checkpoint blockade (ICB) therapy can be associated with the development of bullous pemphigoid (BP). To characterize clinical, histological and serological characteristics, we compared immune-related BP (irBP) and spontaneous BP (sBP) considering clinical, serological and histopathological character.</p><p><strong>Methods: </strong>149 BP patients treated at the University Hospital Zurich between 2015 and 2024 were identified retrospectively. Demographic and serological data were obtained from electronic records. Hematoxylin-eosin (HE)-stained biopsies were semi-quantitatively evaluated for immune cell infiltrates, split formation, and infiltration patterns.</p><p><strong>Results: </strong>From the total of 149 cases, 17 were irBP and 132 were sBP. Patients affected by irBP were predominantly males (94%), females were slightly overrepresented in sBP (51.5%) and BP was less often suspected at presentation (59% vs 85% in sBP). Anti-BP230 antibodies were more frequently elevated in sBP (64.4% vs 23.5% in irBP). Histologically, irBP cases showed denser neutrophilic, eosinophilic, and lymphocytic infiltrates, as assessed by semi-quantitative scoring.</p><p><strong>Conclusion: </strong>irBP differs from sBP by showing denser immune-infiltrates, lower rates of elevated anti-BP230 antibodies and predominantly affect males. These observations suggest that irBP represents a distinct subtype and highlight the need for diagnostic awareness in the setting of ICB therapy.</p>","PeriodicalId":11185,"journal":{"name":"Dermatology","volume":" ","pages":"1-16"},"PeriodicalIF":2.7,"publicationDate":"2026-04-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147716203","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Predictors of Super/Poor Omalizumab Response in Chinese Refractory Chronic Spontaneous Urticaria.","authors":"Anqi Chen, Huan Yang, Xianjie Yang, Xuewei Huang, Shifei Li, Sisi Deng, Huan Wang, Zhiqiang Song, Qiquan Chen","doi":"10.1159/000551762","DOIUrl":"https://doi.org/10.1159/000551762","url":null,"abstract":"<p><strong>Background: </strong>Omalizumab is an effective treatment for antihistamine-refractory chronic spontaneous urticaria (CSU), although treatment responses can vary significantly. While fast and slow responders are well-characterized, the profile of super-responders (SR) remains poorly understood.</p><p><strong>Objective: </strong>To identify clinical and laboratory predictors of SR and poor/non-response (PR) to omalizumab in refractory CSU.</p><p><strong>Methods: </strong>This retrospective study analyzed 307 CSU patients treated with omalizumab at a UCARE center between January 2023 and December 2024. SR was defined as achieving Urticaria Activity Score(UAS)=0 within 1 week and sustained control (UAS7≤6, UCT > 12); PR had the Urticaria Control Test (UCT)< 12 after three injections. Demographic, clinical, and laboratory parameters were compared.</p><p><strong>Results: </strong>SR patients (n=138) had lower rates of concomitant chronic inducible urticaria (CIndU) (26.8% vs. 48.5%, P<0.05), higher total Immunoglobulin E (IgE) (113.0 IU/mL), and elevated D-dimer. PR patients (n=35) were older (median 52.0 years), had higher angioedema rates (65.5%), lower atopy prevalence (47.1%), higher UAS7 scores, lower IgE (53.5 IU/mL), and higher autologous serum skin test(ASST) positivity (61.5%). Multivariate analysis identified male sex as protective for SR (OR = 0.556, P=0.025), while concomitant CIndU predicted non-SR (odds ratio, OR = 2.357, P=0.001). Predictors of PR included Body Mass Index (BMI) ≥28 kg/m² (OR = 5.147, P=0.023), angioedema (OR = 3.309, P=0.042), and ASST positivity (OR = 4.174, P=0.011); atopy was protective (OR = 0.299, P=0.025).</p><p><strong>Conclusion: </strong>Male sex and absence of CIndU predict super-response to omalizumab, while high BMI, angioedema, and ASST positivity predict poor response. Atopy is associated with better omalizumab response. These findings support personalized treatment strategies in refractory CSU, though further multiethnic validation is warranted.</p>","PeriodicalId":11185,"journal":{"name":"Dermatology","volume":" ","pages":"1-17"},"PeriodicalIF":2.7,"publicationDate":"2026-04-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147716408","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Primary Care Teleconsultations in Hidradenitis Suppurativa: Characteristics and Clinical Decision-Making.","authors":"Julia Castro Martín, Andrea Isabel Rodríguez-Sanna, Clara Ureña-Paniego, Alberto Soto-Moreno, José Juan Jiménez Moleón, Salvador Arias-Santiago, Alejandro Molina-Leyva","doi":"10.1159/000551423","DOIUrl":"https://doi.org/10.1159/000551423","url":null,"abstract":"<p><strong>Background: </strong>Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease in which diagnosis and treatment may modify the course. Teleconsultation (TC) between primary care (PC) and dermatology can expedite referrals. We aimed to (1) assess PC recognition of HS using TC free-text terminology and its impact, and (2) determine concordance between TC and in-person evaluation in staging (Hurley, International HS Severity Score System [IHS4]) and treatment.</p><p><strong>Methods: </strong>Cross-sectional study of patients referred via TC to a hospital HS unit (May 2024-May 2025). A blinded HS expert reviewed narratives, assigned Hurley stage, calculated IHS4, and proposed graded treatment (topical, oral antibiotic, biologic). Agreement with in-person assessment (examination ± ultrasound [US]) was analyzed using weighted Cohen's kappa (κ), Bland-Altman plots, and paired t-tests.</p><p><strong>Results: </strong>One hundred patients were included (mean age 37.9 ± 14.4 years; 53% women). \"Hidradenitis suppurativa\" appeared in 57% of TCs; omission correlated with inflammatory nodules, Hurley I, and atypical or inguinogenital phenotypes. TC underestimated severity: 57% (25/44) of in-person Hurley II were graded as Hurley I in TC; mean TC-IHS4 was lower than in-person IHS4 (3.9 vs 6.4; mean difference +2.5; p < 0.001). TC-based treatment matched in 50%, was more intensive in 27%, and less intensive in 23%.</p><p><strong>Conclusions: </strong>Half of PC referrals omit the HS label, in mild or atypical forms. TC tends to underestimate severity and yields 50% therapeutic concordance, risking under- or overtreatment. Strengthening PC education and combining TC with physical examination and US may improve HS care.</p>","PeriodicalId":11185,"journal":{"name":"Dermatology","volume":" ","pages":"1-14"},"PeriodicalIF":2.7,"publicationDate":"2026-04-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147716368","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Practitioner-reported complications in tattoo removal.","authors":"Mila Poelhekken, Peter J Velthuis, Esther P M Tjin, Darisa A K Quant, Sebastiaan A S van der Bent","doi":"10.1159/000551910","DOIUrl":"https://doi.org/10.1159/000551910","url":null,"abstract":"<p><p>Background Q-switched laser treatment is the gold standard for tattoo removal, however complications such as blistering, scarring, dyspigmentation, infections and allergic reactions can occur. Potential risk factors include the client skin type, tattoo age, and ink colour. Moreover, untrained practitioners performing laser tattoo removal, and the increasing use of non-evidence-based alternative removal products have raised safety concerns. This study aimed to document practitioner-reported complications in laser tattoo removal, focusing on frequency and associating factors. Secondary objectives were to explore practitioner-reported encounters with alternative removal techniques and treatments performed by untrained practitioners. Methods A digital survey containing up to 41 questions was distributed among Dutch dermal therapists. The survey addressed treatment protocols, complications of laser tattoo removal and observations regarding alternative techniques and untrained practitioners in tattoo removal. Results Of 173 practitioners, 94 (54.3%) actively practiced laser tattoo removal. Complications were reported in an estimated 8.1% of laser tattoo removal treatment sessions, most commonly oedema (3.0%), blistering (1.9%) and haematoma (0.7%). Hypo- and hyperpigmentation were reported in approximately 0.6% of treatments, while hypertrophic scarring and paradoxical darkening were reported in 0.2%. Keloid formation, allergic reactions, ink blow-out and infection were each reported in 0.1%. Complications were reported more frequently by practitioners treating clients with Fitzpatrick skin types ≥III, coloured tattoos, permanent make-up, previously treated tattoos and tattoos younger than one year. Among practitioners performing laser tattoo removal, 87% reported treating clients previously treated by untrained practitioners, and 81.7% of these practitioners observed complications. Additionally, 31.0% of all practitioners reported clients who had used alternative removal techniques, with complications observed in 56.7%. Conclusions This is the first study to systematically report practitioner-reported complications in laser tattoo removal. Although laser tattoo removal is generally safe, complications were more frequently reported in the presence of known risk factors. The widespread involvement of untrained practitioners and the use of alternative removal techniques highlight ongoing safety concerns and underscore the need for further research and consideration of regulatory measures.</p>","PeriodicalId":11185,"journal":{"name":"Dermatology","volume":" ","pages":"1-15"},"PeriodicalIF":2.7,"publicationDate":"2026-04-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147688785","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy of Gabapentin Combined with Standard-dose Antihistamines versus Antihistamine Monotherapy in Prurigo Nodularis: A Prospective Monocentric Real-world Observational Study.","authors":"Duoqin Wang, Taiyu Jin, Lisi Peng, Yanyun Shen, Yiqi Zhu, Zijin Xiao, WenLi Zhang, Shuwen Xu, Yixin Shao, Hui Tang","doi":"10.1159/000551865","DOIUrl":"https://doi.org/10.1159/000551865","url":null,"abstract":"<p><strong>Introduction: </strong>Prurigo nodularis (PN), the most common subtype of Chronic prurigo, is a chronic pruritic dermatosis. Although gabapentin has been proposed as a second-line treatment for PN, clinical studies assessing its efficacy and safety for PN remain limited. This study evaluated the efficacy and safety of gabapentin in the management of PN and to explore an effective and well-tolerated dosing regimen.</p><p><strong>Methods: </strong>In the 12-week prospective real-world observational study, 26 patients with PN were allocated to receive either gabapentin (initial dose 300 mg/day) combined with standard-dose antihistamines (combination group) or standard-dose antihistamine monotherapy (monotherapy group). Dose adjustments of gabapentin were made depending on therapeutic response biweekly, with a maximum of 900 mg daily. Efficacy was assessed using the Peak Pruritus Numerical Rating Scale (PP-NRS), Sleep Disturbance-Numerical Rating Scale (SD-NRS), Dermatology Life Quality Index (DLQI), and Hospital Anxiety and Depression Scale (HADS), and Investigator's Global Assessment (IGA) scores. Itching response was defined as a reduction of the PP-NRS scores that is greater than 50% or 4 points compared with baseline.</p><p><strong>Results: </strong>Compared to monotherapy group (n=14), the combination group (n=12) exhibited significantly lower PP-NRS and HADS scores as early as week 2, and a higher proportion of patients showing itching response (75.0% vs. 35.7%). The majority (77.8%) of patients in the combination group reached the itching response at week 12 under 600 mg of gabapentin daily. Adverse effects were mild and resolved following dose reduction.</p><p><strong>Conclusion: </strong>Gabapentin provides faster and superior efficacy in reducing pruritus and anxiety and depression for patients with PN, with a favorable safety profile.</p>","PeriodicalId":11185,"journal":{"name":"Dermatology","volume":" ","pages":"1-15"},"PeriodicalIF":2.7,"publicationDate":"2026-04-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147653911","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluation of the contribution of repeat Total Body Photography (TBP) for the early diagnosis of melanoma.","authors":"Amjad Zoabi, Itay Shavit, Tomer Mimouni, Hana Feuerman, Ofer Reiter","doi":"10.1159/000551974","DOIUrl":"https://doi.org/10.1159/000551974","url":null,"abstract":"<p><strong>Introduction: </strong>Early detection of cutaneous melanoma is crucial, as prognosis is strongly determined by Breslow thickness. Total-body photography (TBP) is increasingly used in high-risk populations, yet optimal surveillance strategies remain undefined. In our study, we aimed to evaluate how different follow-up approaches, including those incorporating TBP at varying frequencies, influence the early diagnosis of melanoma, as measured by Breslow thickness.</p><p><strong>Methods: </strong>This retrospective cohort study included adult patients diagnosed with primary cutaneous melanoma at Rabin Medical Center between 2020 and 2025. Melanomas were classified into four groups according to the clinical setting at diagnosis: non-high-risk clinics; first visit to a high-risk clinic before TBP; high-risk follow-up with prior TBP only; and high-risk follow-up with both prior and repeat TBP on the day of diagnosis. Demographic, clinical, and histopathologic data were extracted. Differences in Breslow thickness were analyzed using analysis of covariance, and invasive versus in situ melanoma rates were assessed using multivariable logistic regression.</p><p><strong>Results: </strong>A total of 282 melanomas from 249 patients were analyzed. Melanomas diagnosed in non-high-risk clinics were significantly thicker than those diagnosed in high-risk clinics (adjusted mean Breslow difference: 0.78 mm). Surveillance strategy was associated with invasiveness: invasive melanoma rates were highest in non-high-risk clinics (52%), followed by first-visit to high-risk clinic (39%), patients with prior TBP only (34%), and lowest in patients diagnosed during repeat TBP (20%; overall model p = 0.03). Overall Breslow thickness did not differ significantly between melanomas diagnosed during visits with prior TBP alone and those diagnosed during repeat TBP.</p><p><strong>Conclusion: </strong>High-risk melanoma clinics incorporating TBP are associated with earlier melanoma detection and lower rates of invasive disease. Repeated TBP was associated with lower rate of invasive melanoma compared with baseline TBP and manual comparison on the day of diagnosis.</p>","PeriodicalId":11185,"journal":{"name":"Dermatology","volume":" ","pages":"1-12"},"PeriodicalIF":2.7,"publicationDate":"2026-04-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147653972","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Erratum.","authors":"","doi":"10.1159/000551386","DOIUrl":"https://doi.org/10.1159/000551386","url":null,"abstract":"<p><p>The article \"Incidence of Tattoo-Associated Melanoma in the Netherlands (1991-2023): A Nationwide Registry Study\" [Dermatology. 2026;242:58-67; https://doi.org/10.1159/000549503] by Karregat et al. was published with the wrong open access license. The correct license of the article is CC-BY.The original article has been updated.</p>","PeriodicalId":11185,"journal":{"name":"Dermatology","volume":" ","pages":"1"},"PeriodicalIF":2.7,"publicationDate":"2026-04-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147638194","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical and histopathological predictors of disease progression in stage II cutaneous melanoma.","authors":"Luisa Boeti, Laura Del Regno, Lucia Di Nardo, Maria Mannino, Alessandro Di Stefani, Laura Quattrini, Irina Ciobotariu, Marisa Salvi, Ketty Peris","doi":"10.1159/000550996","DOIUrl":"https://doi.org/10.1159/000550996","url":null,"abstract":"<p><strong>Introduction: </strong>The recent approval of pembrolizumab and nivolumab for the adjuvant treatment of stage IIB-IIC cutaneous melanoma (CM) significantly improved the relapse-free survival (RFS) probability of this patient population. Real-life data suggests that not all stage IIB and IIC CM patients will invariably undergo disease progression. There is a growing need for accurate patients' selection for whom adjuvant therapy is expected to be beneficial. The aim of this study was to investigate the baseline clinical and histopathological features associated with tumor recurrence in stage II CM patients in an Italian tertiary referral center.</p><p><strong>Methods: </strong>Patients' clinical features and histopathological tumor characteristics were recorded at the time of melanoma diagnosis. Non-recurrent patients were defined based on a  5-year follow-up period; time to disease recurrence was calculated as the time from the diagnosis of the primary tumor until first evidence of melanoma relapse.</p><p><strong>Results: </strong>103 stage II CM patients, with a median follow-up of 6.2 years were included. Twenty-one of 103 (20.4%) patients recurred, of whom 15/21 (71.4%) showed disease progression to stage IV disease. Breslow thickness was significantly associated with CM recurrence, with a 70% increased probability of melanoma relapse per each unit increase in Breslow thickness (mm) (OR=1.7; 95% CI:1.05-2.7; p=0.029). Histopathological evidence of ulceration and the mitotic rate did not show a significant association with melanoma progression. Breslow thickness was also associated with a reduced time from melanoma diagnosis to recurrence per each unit increase (mm) (p=0.032), and with shorter disease-free survival probability (HR: 1.47; 95% CI: 1.05-2.06; p=0.025).</p><p><strong>Conclusion: </strong>Breslow thickness is a relevant prognostic factor for CM recurrence. Further studies are needed to identify novel prognostic biomarkers.</p>","PeriodicalId":11185,"journal":{"name":"Dermatology","volume":" ","pages":"1-16"},"PeriodicalIF":2.7,"publicationDate":"2026-04-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147608295","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Atopic Dermatitis in Urban Indonesian Children: A Case-Control Study of the Prevalence of Filaggrin Loss-of-Function Variants and Sociodemographic Factors at a Tertiary Referral Hospital.","authors":"Raden Mohamad Rendy Ariezal Effendi, Luba M Pardo, Reiva Farah Dwiyana, Oki Suwarsa, Michel van Geel, Yunia Sribudiani, Tamar E C Nijsten, Hok Bing Thio","doi":"10.1159/000551761","DOIUrl":"https://doi.org/10.1159/000551761","url":null,"abstract":"<p><strong>Introduction: </strong>Research on atopic dermatitis (AD) in children has predominantly focused on European and Western populations. Although there is evidence suggesting a connection between sociodemographic and cultural factors and AD, studies involving Asian populations are notably limited. This study profiled filaggrin (FLG) loss-of-function (LOF) variants, estimates their prevalence, and investigates the association between sociodemographic and cultural factors with AD among children in Indonesia as one of the most densely populated developing countries in Asia.</p><p><strong>Methods: </strong>A case control study was conducted at the Pediatric Dermatology Clinic of Dr. Hasan Sadikin General Hospital in Bandung, the capital city of West Java, Indonesia. Children were included from April to December 2022. AD was diagnosed using Hanifin and Rajka criteria. Controls were children without AD of similar age and sex. Sociodemographic data were collected. We sequenced the coding region of FLG using single-molecule molecular inversion probes and next-generation sequencing. Descriptive statistics were used to summarize demographic characteristics. Univariate and multivariate analysis estimated adjusted odds ratios (aOR) and 95% confidence intervals.</p><p><strong>Results: </strong>We enrolled 218 participants. FLG LOF variants were 3.6% in AD and 1.9% in controls; detected variants included c.7487del, c.2282_2285del, and c.1501C>T. Parental history of atopy is significantly associated with children developing AD, with aOR of 6.59 (95% CI: 3.18-13.63) for mothers and aOR 3.86 (95% CI: 1.73-8.62) for fathers. After adjustment, sociodemographic and cultural variables were not statistically significant in multivariate models.</p><p><strong>Conclusion: </strong>In Indonesian children, FLG LOF variants were infrequent, contrasting with European cohorts. Parental atopy remained a strong determinant, and no independent associations with sociodemographic or cultural factors were detected.</p>","PeriodicalId":11185,"journal":{"name":"Dermatology","volume":" ","pages":"1-19"},"PeriodicalIF":2.7,"publicationDate":"2026-03-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147580425","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}